Protocol for Evaluation of Oncological Treatment in Patients With CRLM Using Zebra Fish Avatars-may This Model Improve Resection Rates and Survival in Patients With Upfront Non-resectable Metastatic Disease?

Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 1/Phase 2
SUMMARY

In order to improve and individualize cancer treatment, personalized treatment needs to be developed much further. Liver metastasizing colorectal cancer is treated with a combination of oncological and surgical interventions. The selection of chemotherapy is today mainly done according to best guess. Today only a small fraction of oncological treatment may be known to be effective in a person before treatment start, most often it is trial and error. A fast reliable system for looking at response to different treatments in each unique patient is much needed and would, if successful, completely change the way we give oncological treatment today. Patient's tumor tissue will be evaluated with use of zebrafish embryo avatars to evaluate tumour growth and response to different combinations of chemotherapy. If successful interventional studies are planned.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Confirmed or suspected diagnosis of colorectal liver metastasis Age 18 years or older ECOG 0-2 Patient can understand verbal and written information -

Locations
Other Locations
Sweden
Per Sandström
RECRUITING
Linköping
Contact Information
Primary
Per Sandström, Prof
per.sandstrom@liu.se
+46734058581
Backup
Bergthor Bjornsson, Prof
bergthor.bjornsson@liu.se
+46101033666
Time Frame
Start Date: 2022-05-17
Estimated Completion Date: 2025-03-14
Participants
Target number of participants: 40
Treatments
Experimental: Colorectal liver metastsis, single arm
Tumour tissue from patients operated for colorectal liver metastases. A cubic centimeter of tumour tissue will be processed and implanted in zebra fish embryos. Tissue in zebrafish embryos will treated with different combinations of chemotherapy. Chemocombination of best effect will be offered patients in the third phase of the trial
Related Therapeutic Areas
Sponsors
Leads: University Hospital, Linkoeping
Collaborators: Medical Research Council of Southeast Sweden, Sahlgrenska University Hospital

This content was sourced from clinicaltrials.gov